Risk Of Developing Liver Cancer After HCV Treatment

Sunday, February 19, 2017

APASL 2017 - Triple DAA combo containing ritonavir effective, safe for HCV GT1b in Asians


Triple DAA combo containing ritonavir effective, safe for HCV GT1b in Asians
13 hours ago, Pearl Toh
A combination of the direct-acting antiviral agents (DAAs) ombitasvir/paritaprevir/ritonavir (OBV/PTV/r) and dasabuvir (DSV) resulted in sustained virologic response at post-treatment week 12 (SVR12) in almost all Asian adult patients with genotype 1b (GT1b) chronic hepatitis C virus (HCV) infection without cirrhosis, according to the ONYX-I* study presented at the recent Asian Pacific Association for the Study of the Liver Annual Meeting (APASL 2017) held in Shanghai, China.

July 25, 2016

No comments:

Post a Comment